Matt Gross
Matt Gross brings over 20 years of broad biotech experience in Business Development, Alliance Management and Drug Development. Most recently he served as Vice President of Business Development at Rapafusyn Pharmaceuticals Inc., where he closed a multi-target Research Collaboration with a top tier Pharma company. Prior to Rapafusyn, he served as VP of Business Development at Calithera Biosciences where he led BD, alliance management, and strategic planning functions. During his time at Calithera he was responsible for closing multiple transactions including an acquisition of clinical stage oncology assets from Takeda. Prior to his role in Business Development, he served as the Director of Pharmacology at Calithera.
Mr. Gross has a diverse scientific background in pharmacology, toxicology and translational medicine. Prior to Calithera, he served as Scientist II at Adamas Pharmaceuticals. Mr. Gross has held scientific positions with increasing responsibility at Adamas Pharmaceuticals, Avigen Inc., Xoma Corporation and GeneSoft Inc. He received his Bachelor of Science in Biological Sciences from University of California, Santa Barbara.
Learn more about Matt
